News

JAK2 inhibitor, is Lilly’s early stage investigational proprietarycompound, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms. The new

The issued patents cover the class of selective 5-HT compounds of Suven that are being developed to treat cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention

The product is based on BLIS K12, which supports the body’s immune system and provides natural and active defense against bacterial imbalance in the mouth, fighting antagonistic bacteria

Esomeprazole is a generic bio-equivalent version of the product Nexium in the UK. Esomeprazole is used to treat dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and

Under the deal, both the parties have signed a Joint Statement on the role of pharmacists in tuberculosis care and control. The agreement aims to increase awareness of

Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases. Astellas will pay a sum of

Discovered by PTC, ataluren is an experimental protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense

The approval was backed by the results of RAD001 In Advanced Neuroendocrine Tumors (RADIANT-3) Phase III trial which demonstrated that the treatment with Afinitor more than doubled the

Currently, the company is in quest of a partner who can fund further development and marketing of the product. Centre for Endocrinology and Diabetes Sciences clinical professor David